诺诚健华企业传播执行总监陆春华表示：“中国创新药的知识产权授权给了国际的MNC公司，今年上半年的总的对外授权的总金额，已经达到了600亿美元，超过了2024年全年，那尤其在前几年资本市场相对比较薄弱的情况下，中国创新药通过对外授权获得的资本，足以支撑创新药的发展，因为它几乎超过了IPO的融资，这几年中国的创新药已经成为这个世界创新的名片。”
Source Link诺诚健华企业传播执行总监陆春华表示：“中国创新药的知识产权授权给了国际的MNC公司，今年上半年的总的对外授权的总金额，已经达到了600亿美元，超过了2024年全年，那尤其在前几年资本市场相对比较薄弱的情况下，中国创新药通过对外授权获得的资本，足以支撑创新药的发展，因为它几乎超过了IPO的融资，这几年中国的创新药已经成为这个世界创新的名片。”
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.